Therapeutic drug monitoring of tricyclic antidepressants: How does it work under clinical conditions?

Therapeutic drug monitoring (TDM) of tricyclic antidepressants (TCA) is established in the treatment of depression to optimize outcome and safety. However, there are few reports on TDM under naturalistic clinical conditions. In the present study, we investigated a TDM group (TDM) and a randomly assi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmacopsychiatry 2003-05, Vol.36 (3), p.98-104
Hauptverfasser: MÜLLER, M. J, DRAGICEVIC, A, RAO, M. L, ROLLMANN, N, WEIGMANN, H, WEBER-LABONTE, M, HLEMKE, C, FRIC, M, GAERTNER, I, GRASMÄDER, K, HÄRTTER, S, HERMANN, E, KUSS, H. J, LAUX, G, OEHL, W
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 104
container_issue 3
container_start_page 98
container_title Pharmacopsychiatry
container_volume 36
creator MÜLLER, M. J
DRAGICEVIC, A
RAO, M. L
ROLLMANN, N
WEIGMANN, H
WEBER-LABONTE, M
HLEMKE, C
FRIC, M
GAERTNER, I
GRASMÄDER, K
HÄRTTER, S
HERMANN, E
KUSS, H. J
LAUX, G
OEHL, W
description Therapeutic drug monitoring (TDM) of tricyclic antidepressants (TCA) is established in the treatment of depression to optimize outcome and safety. However, there are few reports on TDM under naturalistic clinical conditions. In the present study, we investigated a TDM group (TDM) and a randomly assigned parallel group without TDM (no-TDM) while on TCA treatment. Serum levels were analyzed in both cohorts, but feedback and dose recommendation were only provided for the TDM group. Serum levels of TCA were assessed by high-performance liquid chromatography (HPLC). The outcome was measured weekly using the Hamilton Depression Rating Scale (HAMD), the Clinical Global Impressions Scale (CGI), and the UKU side-effect scale. 84 patients with depressive disorder according to DSM-IV were recruited in three centers (TDM, n = 43; no-TDM, n = 41; mean age 49.9 +/- 13.2 years, 63.1 % female). Patients were treated with either amitriptyline (n = 69) or doxepin (n = 15); the mean dosage at endpoint was 126 +/- 35 mg and 155 +/- 47 mg, respectively. The mean study duration was 21 +/- 8 days. Both groups improved according to HAMD (from 25.2 +/- 8.4 at baseline to 12.0 +/- 7.4 at endpoint) and CGI scores (68 % responders). Moderately severe or severe side effects occurred in 16 % of patients. Adequate dose adjustment was significantly higher in the TDM group (60 % vs. 46 %, p < 0.05); this led to a significantly higher rate of therapeutic serum levels in the TDM group (58 % vs. 44 %, p < 0.05). Direct effects of TDM were not found for effectiveness. Therapeutic TCA serum levels over weeks one to three, however, were associated with significantly better outcome at endpoint (p < 0.05) as measured with changes in the HAMD or CGI response rates from baseline to endpoint. Finally, considerable side effects occurred significantly more often when serum levels were above the therapeutic range (27 % vs. 11 %; p < 0.01). We conclude that treating depression with TCA can be optimized by early TDM, which is superior to clinical judgment on its own. Since the psychiatrists in charge were less than completely "compliant" to the recommendations provided together with serum levels, the effect could be more pronounced than this study shows. The results encourage further studies in order to optimize antidepressant pharmacotherapy when using TDM appropriately.
doi_str_mv 10.1055/s-2003-39983
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1055_s_2003_39983</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>12806567</sourcerecordid><originalsourceid>FETCH-LOGICAL-c317t-56493e34e63b9492a50b4331e2a6af005a964bad30459918a6d5cc525d88bdf93</originalsourceid><addsrcrecordid>eNpF0MFLwzAUBvAgipvTm2fJxZvVpC9JGy8yhjph4GWeS5qkM7olJWkZ--_t3GCn9-D9-OB9CN1S8kgJ508pywmBDKQs4QyNKQOZkULyczQmtBAZiEKO0FVKP4RQJglcohHNSyK4KMbILr9tVK3tO6exif0Kb4J3XYjOr3BocBed3un1cFS-c8a20aY0rOkZz8MWm2ATdh3ehviLe29sxAP2Tqs11sEb17ng08s1umjUOtmb45ygr7fX5WyeLT7fP2bTRaaBFl3GBZNggVkBtWQyV5zUDIDaXAnVEMKVFKxWBgjjUtJSCcO15jk3ZVmbRsIEPRxydQwpRdtUbXQbFXcVJdW-rSpV-7aq_7YGfnfgbV9vrDnhYz0DuD8ClYaXmqi8dunkWFlIGIL-AEtOcyc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Therapeutic drug monitoring of tricyclic antidepressants: How does it work under clinical conditions?</title><source>MEDLINE</source><source>Thieme Connect Journals</source><creator>MÜLLER, M. J ; DRAGICEVIC, A ; RAO, M. L ; ROLLMANN, N ; WEIGMANN, H ; WEBER-LABONTE, M ; HLEMKE, C ; FRIC, M ; GAERTNER, I ; GRASMÄDER, K ; HÄRTTER, S ; HERMANN, E ; KUSS, H. J ; LAUX, G ; OEHL, W</creator><creatorcontrib>MÜLLER, M. J ; DRAGICEVIC, A ; RAO, M. L ; ROLLMANN, N ; WEIGMANN, H ; WEBER-LABONTE, M ; HLEMKE, C ; FRIC, M ; GAERTNER, I ; GRASMÄDER, K ; HÄRTTER, S ; HERMANN, E ; KUSS, H. J ; LAUX, G ; OEHL, W</creatorcontrib><description>Therapeutic drug monitoring (TDM) of tricyclic antidepressants (TCA) is established in the treatment of depression to optimize outcome and safety. However, there are few reports on TDM under naturalistic clinical conditions. In the present study, we investigated a TDM group (TDM) and a randomly assigned parallel group without TDM (no-TDM) while on TCA treatment. Serum levels were analyzed in both cohorts, but feedback and dose recommendation were only provided for the TDM group. Serum levels of TCA were assessed by high-performance liquid chromatography (HPLC). The outcome was measured weekly using the Hamilton Depression Rating Scale (HAMD), the Clinical Global Impressions Scale (CGI), and the UKU side-effect scale. 84 patients with depressive disorder according to DSM-IV were recruited in three centers (TDM, n = 43; no-TDM, n = 41; mean age 49.9 +/- 13.2 years, 63.1 % female). Patients were treated with either amitriptyline (n = 69) or doxepin (n = 15); the mean dosage at endpoint was 126 +/- 35 mg and 155 +/- 47 mg, respectively. The mean study duration was 21 +/- 8 days. Both groups improved according to HAMD (from 25.2 +/- 8.4 at baseline to 12.0 +/- 7.4 at endpoint) and CGI scores (68 % responders). Moderately severe or severe side effects occurred in 16 % of patients. Adequate dose adjustment was significantly higher in the TDM group (60 % vs. 46 %, p &lt; 0.05); this led to a significantly higher rate of therapeutic serum levels in the TDM group (58 % vs. 44 %, p &lt; 0.05). Direct effects of TDM were not found for effectiveness. Therapeutic TCA serum levels over weeks one to three, however, were associated with significantly better outcome at endpoint (p &lt; 0.05) as measured with changes in the HAMD or CGI response rates from baseline to endpoint. Finally, considerable side effects occurred significantly more often when serum levels were above the therapeutic range (27 % vs. 11 %; p &lt; 0.01). We conclude that treating depression with TCA can be optimized by early TDM, which is superior to clinical judgment on its own. Since the psychiatrists in charge were less than completely "compliant" to the recommendations provided together with serum levels, the effect could be more pronounced than this study shows. The results encourage further studies in order to optimize antidepressant pharmacotherapy when using TDM appropriately.</description><identifier>ISSN: 0176-3679</identifier><identifier>EISSN: 1439-0795</identifier><identifier>DOI: 10.1055/s-2003-39983</identifier><identifier>PMID: 12806567</identifier><identifier>CODEN: PHRMEZ</identifier><language>eng</language><publisher>Stuttgart: Thieme</publisher><subject>Amitriptyline - adverse effects ; Amitriptyline - blood ; Amitriptyline - therapeutic use ; Antidepressive Agents, Tricyclic - adverse effects ; Antidepressive Agents, Tricyclic - blood ; Antidepressive Agents, Tricyclic - therapeutic use ; Biological and medical sciences ; Depressive Disorder - blood ; Depressive Disorder - drug therapy ; Doxepin - adverse effects ; Doxepin - blood ; Doxepin - therapeutic use ; Drug Monitoring - methods ; Female ; Humans ; Male ; Medical sciences ; Middle Aged ; Psychiatric Status Rating Scales ; Treatment Outcome</subject><ispartof>Pharmacopsychiatry, 2003-05, Vol.36 (3), p.98-104</ispartof><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c317t-56493e34e63b9492a50b4331e2a6af005a964bad30459918a6d5cc525d88bdf93</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,3017,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=14879383$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12806567$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MÜLLER, M. J</creatorcontrib><creatorcontrib>DRAGICEVIC, A</creatorcontrib><creatorcontrib>RAO, M. L</creatorcontrib><creatorcontrib>ROLLMANN, N</creatorcontrib><creatorcontrib>WEIGMANN, H</creatorcontrib><creatorcontrib>WEBER-LABONTE, M</creatorcontrib><creatorcontrib>HLEMKE, C</creatorcontrib><creatorcontrib>FRIC, M</creatorcontrib><creatorcontrib>GAERTNER, I</creatorcontrib><creatorcontrib>GRASMÄDER, K</creatorcontrib><creatorcontrib>HÄRTTER, S</creatorcontrib><creatorcontrib>HERMANN, E</creatorcontrib><creatorcontrib>KUSS, H. J</creatorcontrib><creatorcontrib>LAUX, G</creatorcontrib><creatorcontrib>OEHL, W</creatorcontrib><title>Therapeutic drug monitoring of tricyclic antidepressants: How does it work under clinical conditions?</title><title>Pharmacopsychiatry</title><addtitle>Pharmacopsychiatry</addtitle><description>Therapeutic drug monitoring (TDM) of tricyclic antidepressants (TCA) is established in the treatment of depression to optimize outcome and safety. However, there are few reports on TDM under naturalistic clinical conditions. In the present study, we investigated a TDM group (TDM) and a randomly assigned parallel group without TDM (no-TDM) while on TCA treatment. Serum levels were analyzed in both cohorts, but feedback and dose recommendation were only provided for the TDM group. Serum levels of TCA were assessed by high-performance liquid chromatography (HPLC). The outcome was measured weekly using the Hamilton Depression Rating Scale (HAMD), the Clinical Global Impressions Scale (CGI), and the UKU side-effect scale. 84 patients with depressive disorder according to DSM-IV were recruited in three centers (TDM, n = 43; no-TDM, n = 41; mean age 49.9 +/- 13.2 years, 63.1 % female). Patients were treated with either amitriptyline (n = 69) or doxepin (n = 15); the mean dosage at endpoint was 126 +/- 35 mg and 155 +/- 47 mg, respectively. The mean study duration was 21 +/- 8 days. Both groups improved according to HAMD (from 25.2 +/- 8.4 at baseline to 12.0 +/- 7.4 at endpoint) and CGI scores (68 % responders). Moderately severe or severe side effects occurred in 16 % of patients. Adequate dose adjustment was significantly higher in the TDM group (60 % vs. 46 %, p &lt; 0.05); this led to a significantly higher rate of therapeutic serum levels in the TDM group (58 % vs. 44 %, p &lt; 0.05). Direct effects of TDM were not found for effectiveness. Therapeutic TCA serum levels over weeks one to three, however, were associated with significantly better outcome at endpoint (p &lt; 0.05) as measured with changes in the HAMD or CGI response rates from baseline to endpoint. Finally, considerable side effects occurred significantly more often when serum levels were above the therapeutic range (27 % vs. 11 %; p &lt; 0.01). We conclude that treating depression with TCA can be optimized by early TDM, which is superior to clinical judgment on its own. Since the psychiatrists in charge were less than completely "compliant" to the recommendations provided together with serum levels, the effect could be more pronounced than this study shows. The results encourage further studies in order to optimize antidepressant pharmacotherapy when using TDM appropriately.</description><subject>Amitriptyline - adverse effects</subject><subject>Amitriptyline - blood</subject><subject>Amitriptyline - therapeutic use</subject><subject>Antidepressive Agents, Tricyclic - adverse effects</subject><subject>Antidepressive Agents, Tricyclic - blood</subject><subject>Antidepressive Agents, Tricyclic - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Depressive Disorder - blood</subject><subject>Depressive Disorder - drug therapy</subject><subject>Doxepin - adverse effects</subject><subject>Doxepin - blood</subject><subject>Doxepin - therapeutic use</subject><subject>Drug Monitoring - methods</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Psychiatric Status Rating Scales</subject><subject>Treatment Outcome</subject><issn>0176-3679</issn><issn>1439-0795</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpF0MFLwzAUBvAgipvTm2fJxZvVpC9JGy8yhjph4GWeS5qkM7olJWkZ--_t3GCn9-D9-OB9CN1S8kgJ508pywmBDKQs4QyNKQOZkULyczQmtBAZiEKO0FVKP4RQJglcohHNSyK4KMbILr9tVK3tO6exif0Kb4J3XYjOr3BocBed3un1cFS-c8a20aY0rOkZz8MWm2ATdh3ehviLe29sxAP2Tqs11sEb17ng08s1umjUOtmb45ygr7fX5WyeLT7fP2bTRaaBFl3GBZNggVkBtWQyV5zUDIDaXAnVEMKVFKxWBgjjUtJSCcO15jk3ZVmbRsIEPRxydQwpRdtUbXQbFXcVJdW-rSpV-7aq_7YGfnfgbV9vrDnhYz0DuD8ClYaXmqi8dunkWFlIGIL-AEtOcyc</recordid><startdate>20030501</startdate><enddate>20030501</enddate><creator>MÜLLER, M. J</creator><creator>DRAGICEVIC, A</creator><creator>RAO, M. L</creator><creator>ROLLMANN, N</creator><creator>WEIGMANN, H</creator><creator>WEBER-LABONTE, M</creator><creator>HLEMKE, C</creator><creator>FRIC, M</creator><creator>GAERTNER, I</creator><creator>GRASMÄDER, K</creator><creator>HÄRTTER, S</creator><creator>HERMANN, E</creator><creator>KUSS, H. J</creator><creator>LAUX, G</creator><creator>OEHL, W</creator><general>Thieme</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20030501</creationdate><title>Therapeutic drug monitoring of tricyclic antidepressants: How does it work under clinical conditions?</title><author>MÜLLER, M. J ; DRAGICEVIC, A ; RAO, M. L ; ROLLMANN, N ; WEIGMANN, H ; WEBER-LABONTE, M ; HLEMKE, C ; FRIC, M ; GAERTNER, I ; GRASMÄDER, K ; HÄRTTER, S ; HERMANN, E ; KUSS, H. J ; LAUX, G ; OEHL, W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c317t-56493e34e63b9492a50b4331e2a6af005a964bad30459918a6d5cc525d88bdf93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Amitriptyline - adverse effects</topic><topic>Amitriptyline - blood</topic><topic>Amitriptyline - therapeutic use</topic><topic>Antidepressive Agents, Tricyclic - adverse effects</topic><topic>Antidepressive Agents, Tricyclic - blood</topic><topic>Antidepressive Agents, Tricyclic - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Depressive Disorder - blood</topic><topic>Depressive Disorder - drug therapy</topic><topic>Doxepin - adverse effects</topic><topic>Doxepin - blood</topic><topic>Doxepin - therapeutic use</topic><topic>Drug Monitoring - methods</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Psychiatric Status Rating Scales</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MÜLLER, M. J</creatorcontrib><creatorcontrib>DRAGICEVIC, A</creatorcontrib><creatorcontrib>RAO, M. L</creatorcontrib><creatorcontrib>ROLLMANN, N</creatorcontrib><creatorcontrib>WEIGMANN, H</creatorcontrib><creatorcontrib>WEBER-LABONTE, M</creatorcontrib><creatorcontrib>HLEMKE, C</creatorcontrib><creatorcontrib>FRIC, M</creatorcontrib><creatorcontrib>GAERTNER, I</creatorcontrib><creatorcontrib>GRASMÄDER, K</creatorcontrib><creatorcontrib>HÄRTTER, S</creatorcontrib><creatorcontrib>HERMANN, E</creatorcontrib><creatorcontrib>KUSS, H. J</creatorcontrib><creatorcontrib>LAUX, G</creatorcontrib><creatorcontrib>OEHL, W</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Pharmacopsychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MÜLLER, M. J</au><au>DRAGICEVIC, A</au><au>RAO, M. L</au><au>ROLLMANN, N</au><au>WEIGMANN, H</au><au>WEBER-LABONTE, M</au><au>HLEMKE, C</au><au>FRIC, M</au><au>GAERTNER, I</au><au>GRASMÄDER, K</au><au>HÄRTTER, S</au><au>HERMANN, E</au><au>KUSS, H. J</au><au>LAUX, G</au><au>OEHL, W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Therapeutic drug monitoring of tricyclic antidepressants: How does it work under clinical conditions?</atitle><jtitle>Pharmacopsychiatry</jtitle><addtitle>Pharmacopsychiatry</addtitle><date>2003-05-01</date><risdate>2003</risdate><volume>36</volume><issue>3</issue><spage>98</spage><epage>104</epage><pages>98-104</pages><issn>0176-3679</issn><eissn>1439-0795</eissn><coden>PHRMEZ</coden><abstract>Therapeutic drug monitoring (TDM) of tricyclic antidepressants (TCA) is established in the treatment of depression to optimize outcome and safety. However, there are few reports on TDM under naturalistic clinical conditions. In the present study, we investigated a TDM group (TDM) and a randomly assigned parallel group without TDM (no-TDM) while on TCA treatment. Serum levels were analyzed in both cohorts, but feedback and dose recommendation were only provided for the TDM group. Serum levels of TCA were assessed by high-performance liquid chromatography (HPLC). The outcome was measured weekly using the Hamilton Depression Rating Scale (HAMD), the Clinical Global Impressions Scale (CGI), and the UKU side-effect scale. 84 patients with depressive disorder according to DSM-IV were recruited in three centers (TDM, n = 43; no-TDM, n = 41; mean age 49.9 +/- 13.2 years, 63.1 % female). Patients were treated with either amitriptyline (n = 69) or doxepin (n = 15); the mean dosage at endpoint was 126 +/- 35 mg and 155 +/- 47 mg, respectively. The mean study duration was 21 +/- 8 days. Both groups improved according to HAMD (from 25.2 +/- 8.4 at baseline to 12.0 +/- 7.4 at endpoint) and CGI scores (68 % responders). Moderately severe or severe side effects occurred in 16 % of patients. Adequate dose adjustment was significantly higher in the TDM group (60 % vs. 46 %, p &lt; 0.05); this led to a significantly higher rate of therapeutic serum levels in the TDM group (58 % vs. 44 %, p &lt; 0.05). Direct effects of TDM were not found for effectiveness. Therapeutic TCA serum levels over weeks one to three, however, were associated with significantly better outcome at endpoint (p &lt; 0.05) as measured with changes in the HAMD or CGI response rates from baseline to endpoint. Finally, considerable side effects occurred significantly more often when serum levels were above the therapeutic range (27 % vs. 11 %; p &lt; 0.01). We conclude that treating depression with TCA can be optimized by early TDM, which is superior to clinical judgment on its own. Since the psychiatrists in charge were less than completely "compliant" to the recommendations provided together with serum levels, the effect could be more pronounced than this study shows. The results encourage further studies in order to optimize antidepressant pharmacotherapy when using TDM appropriately.</abstract><cop>Stuttgart</cop><cop>New York, NY</cop><pub>Thieme</pub><pmid>12806567</pmid><doi>10.1055/s-2003-39983</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0176-3679
ispartof Pharmacopsychiatry, 2003-05, Vol.36 (3), p.98-104
issn 0176-3679
1439-0795
language eng
recordid cdi_crossref_primary_10_1055_s_2003_39983
source MEDLINE; Thieme Connect Journals
subjects Amitriptyline - adverse effects
Amitriptyline - blood
Amitriptyline - therapeutic use
Antidepressive Agents, Tricyclic - adverse effects
Antidepressive Agents, Tricyclic - blood
Antidepressive Agents, Tricyclic - therapeutic use
Biological and medical sciences
Depressive Disorder - blood
Depressive Disorder - drug therapy
Doxepin - adverse effects
Doxepin - blood
Doxepin - therapeutic use
Drug Monitoring - methods
Female
Humans
Male
Medical sciences
Middle Aged
Psychiatric Status Rating Scales
Treatment Outcome
title Therapeutic drug monitoring of tricyclic antidepressants: How does it work under clinical conditions?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T22%3A10%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Therapeutic%20drug%20monitoring%20of%20tricyclic%20antidepressants:%20How%20does%20it%20work%20under%20clinical%20conditions?&rft.jtitle=Pharmacopsychiatry&rft.au=M%C3%9CLLER,%20M.%20J&rft.date=2003-05-01&rft.volume=36&rft.issue=3&rft.spage=98&rft.epage=104&rft.pages=98-104&rft.issn=0176-3679&rft.eissn=1439-0795&rft.coden=PHRMEZ&rft_id=info:doi/10.1055/s-2003-39983&rft_dat=%3Cpubmed_cross%3E12806567%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/12806567&rfr_iscdi=true